{"disease":{"id":"bipolar-disorder","name":"Bipolar Disorder","therapeutic_area":"Psychiatry","data":{"aiSummary":"The treatment landscape for bipolar disorder primarily involves mood stabilizers like lithium and valproate, along with atypical antipsychotics, which are marketed and widely used. Several agents are in development, including KarXT and lamotrigine, which are in Phase 3 trials and show promise for improving outcomes. Recent advances focus on personalized treatment approaches and the integration of psychotherapy. The pipeline includes novel formulations and combination therapies, aiming to improve efficacy and reduce side effects.","drug_count":13,"description":"Bipolar disorder is a mental health condition characterized by significant shifts in mood, energy, and activity levels, impacting the ability to perform daily tasks. It involves periods of abnormally elevated mood (mania or hypomania) and periods of depression. The pathophysiology involves complex interactions of neurotransmitters, genetics, and environmental factors, leading to dysregulation in mood and behavior. Treatment typically involves a combination of medication and psychotherapy.","subtype_count":12},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.912Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cariprazine","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vraylar","generic_name":"CARIPRAZINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":66,"revenue":"3267","mechanism":"Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior."},{"drug_id":"cariprazine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vraylar","generic_name":"CARIPRAZINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":66,"revenue":"3267","mechanism":"Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior."},{"drug_id":"aripiprazole","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"aripiprazole","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"aripiprazole","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"fluoxetine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prozac","generic_name":"fluoxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":81,"revenue":"1000.0","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown."},{"drug_id":"olanzapine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":38,"revenue":"300","mechanism":null},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":38,"revenue":"300","mechanism":null},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":38,"revenue":"300","mechanism":null},{"drug_id":"olanzapine","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":38,"revenue":"300","mechanism":null},{"drug_id":"lithium-citrate","indication_name":"Bipolar disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Citrate","generic_name":"LITHIUM CITRATE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium","quality_score":67,"revenue":null,"mechanism":"Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes."},{"drug_id":"lithium-citrate","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Citrate","generic_name":"LITHIUM CITRATE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium","quality_score":67,"revenue":null,"mechanism":"Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes."},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"quetiapine","indication_name":"Bipolar disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"quetiapine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"sodium valproate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"samidorphan","indication_name":"Bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":60,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"asenapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphris","generic_name":"ASENAPINE","company_name":"Hisamitsu","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2C","drug_class":"Atypical Antipsychotic [EPC]","quality_score":67,"revenue":null,"mechanism":"Saphris works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2C."},{"drug_id":"asenapine","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphris","generic_name":"ASENAPINE","company_name":"Hisamitsu","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2C","drug_class":"Atypical Antipsychotic [EPC]","quality_score":67,"revenue":null,"mechanism":"Saphris works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2C."},{"drug_id":"phenytoin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenytoin Sodium","generic_name":"PHENYTOIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Sodium channel protein type 2 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":70,"revenue":null,"mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation."},{"drug_id":"carbamazepine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"carbamazepine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"carbamazepine","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"lamotrigine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"risperidone","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Risperdal","generic_name":"risperidone","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Atypical Antipsychotic [EPC]","quality_score":58,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder."},{"drug_id":"risperidone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Risperdal","generic_name":"risperidone","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Atypical Antipsychotic [EPC]","quality_score":58,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder."},{"drug_id":"risperidone","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Risperdal","generic_name":"risperidone","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Atypical Antipsychotic [EPC]","quality_score":58,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder."},{"drug_id":"ziprasidone","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":55,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"ziprasidone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":55,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"ziprasidone","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":55,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"carbamazepin","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"carbamazepin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"carbamazepin","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"valproic-acid","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"prozac","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prozac","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"lithium","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lithium","indication_name":"Bipolar disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lithium","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"phenobarbitone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lithium-carbonate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"lithium-carbonate","indication_name":"Bipolar disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"lithium-carbonate","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"lurasidone","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Latuda","generic_name":"LURASIDONE","company_name":"Sunovion Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":80,"revenue":null,"mechanism":"Latuda works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to regulate mood and reduce symptoms of psychosis."},{"drug_id":"primidone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mysoline","generic_name":"PRIMIDONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 3","drug_class":"Anti-epileptic Agent [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"doxepin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zonalon","generic_name":"DOXEPIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":80,"revenue":null,"mechanism":"Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood."},{"drug_id":"loxapine","indication_name":"Bipolar disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adasuve","generic_name":"LOXAPINE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"loxapine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"dilantin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilantin","generic_name":"Phenytoin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"phenytoin","quality_score":80,"revenue":null,"mechanism":"Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels."},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"seroquel","indication_name":"Bipolar disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"seroquel","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperdal","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risperdal","company_name":"Ohio State University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperdal","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risperdal","company_name":"Ohio State University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperdal","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risperdal","company_name":"Ohio State University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"samidorphan","indication_name":"Bipolar I Disorder - Acute Manic or Mixed Episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":60,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"divalproex","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"samidorphan","indication_name":"Bipolar I Disorder - Maintenance Monotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":60,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"lamotrigine","indication_name":"Bipolar Disorder - Maintenance Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"samidorphan-l-malate","indication_name":"Bipolar I Disorder - Acute Manic or Mixed Episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMIDORPHAN L-MALATE","company_name":"","drug_phase":"marketed","molecular_target":"dopamine and serotonin type 2 (5HT2) receptors, opioid receptors","drug_class":"Atypical Antipsychotic [EPC]","quality_score":55,"revenue":null,"mechanism":"Olanzapine's efficacy may be due to dopamine and serotonin type 2 antagonism, while samidorphan acts through opioid receptor antagonism."},{"drug_id":"samidorphan-l-malate","indication_name":"Bipolar I Disorder - Maintenance Monotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMIDORPHAN L-MALATE","company_name":"","drug_phase":"marketed","molecular_target":"dopamine and serotonin type 2 (5HT2) receptors, opioid receptors","drug_class":"Atypical Antipsychotic [EPC]","quality_score":55,"revenue":null,"mechanism":"Olanzapine's efficacy may be due to dopamine and serotonin type 2 antagonism, while samidorphan acts through opioid receptor antagonism."},{"drug_id":"abilify","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"abilify","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"abilify","indication_name":"Mixed bipolar I disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chlorpromazine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thorazine","generic_name":"chlorpromazine","company_name":"Generic (originally Rhône-Poulenc/Sanofi)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Sphingomyelin phosphodiesterase, 5-hydroxytryptamine receptor 1E","drug_class":"Typical antipsychotic (first-generation, phenothiazine)","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"lithium-citrate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Citrate","generic_name":"LITHIUM CITRATE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium","quality_score":67,"revenue":null,"mechanism":"Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes."}],"pipeline":[],"offLabel":[],"totalMarketed":74,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT06005155","title":"Lithium Versus Anticonvulsants and the Risk of Physical Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":169285,"lead_sponsor_name":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","has_results":false},{"nct_id":"NCT06115200","title":"Norwegian Adult Mental Health Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Helse Stavanger HF","has_results":false},{"nct_id":"NCT07005245","title":"Survey on the Reproductive and Child-Rearing Situations of Patients With Severe Mental Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":77145,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06641726","title":"Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Akrivia Health","has_results":false},{"nct_id":"NCT07281729","title":"Investigation on Risk Factors for Suicide Among Chinese Patients With Mood Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":25000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT06818227","title":"MonPsy&Moi: A Digital Platform for Collecting Patient-Reported Experience and Outcome Measures in Psychiatry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":23660,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT04655287","title":"A Register Study of Effects Following Local Variation in Rates of Involuntary Care","phase":"","overall_status":"COMPLETED","enrollment_count":21759,"lead_sponsor_name":"University Hospital, Akershus","has_results":false},{"nct_id":"NCT05206734","title":"Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health","phase":"","overall_status":"COMPLETED","enrollment_count":19469,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT00024635","title":"Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT02451670","title":"Reducing Cardiovascular Risk in Adults With Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":10347,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT05480150","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT00001174","title":"Evaluation of the Genetics of Bipolar Disorder","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4185,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT03949218","title":"Bipolar Disorder and Oxidative Stress Injury Mechanism - Clinical Big Data Analysis Based on Machine Learning","phase":"","overall_status":"COMPLETED","enrollment_count":3702,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT07129408","title":"Epidemiological Study on the Prevalence of Mental Disorders in Slovakia","phase":"","overall_status":"COMPLETED","enrollment_count":3100,"lead_sponsor_name":"Comenius University","has_results":false},{"nct_id":"NCT06433635","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2726,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT04024553","title":"A Genetic Family Cohort Study of Bipolar Disorder in Chinese Han Population","phase":"","overall_status":"UNKNOWN","enrollment_count":2520,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT00001260","title":"Brain Tissue Collection for Neuropathological Studies","phase":"","overall_status":"TERMINATED","enrollment_count":2161,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT07314190","title":"Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1799,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT03656770","title":"Measuring Beliefs and Norms About Persons With Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":1782,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02456545","title":"Improving Early Recognition and Intervention in At-risk Stages of Bipolar Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":1419,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT03740139","title":"The Police-Mental Health Linkage System","phase":"NA","overall_status":"COMPLETED","enrollment_count":1405,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03451630","title":"Integrated Care (IC) Models for Patient-Centered Outcomes","phase":"NA","overall_status":"COMPLETED","enrollment_count":1400,"lead_sponsor_name":"University of Pittsburgh","has_results":true},{"nct_id":"NCT07239843","title":"Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1310,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT00006177","title":"Child & Adolescent Bipolar Disorder Brain Imaging and Treatment Study","phase":"","overall_status":"COMPLETED","enrollment_count":1303,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT05669703","title":"NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder","phase":"","overall_status":"RECRUITING","enrollment_count":1260,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT02845440","title":"Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":1165,"lead_sponsor_name":"Massachusetts General Hospital","has_results":true},{"nct_id":"NCT03386851","title":"Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder","phase":"","overall_status":"COMPLETED","enrollment_count":1030,"lead_sponsor_name":"Korea Otsuka Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03656302","title":"Circadian Rhythm Dysregulation in Offspring of Parents With Bipolar Disorder","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07173842","title":"NeuroPsyBiT-BD Omics: Genomic & Epigenomic Biobank of Bipolar Disorder","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Selçuk State Hospital","has_results":false},{"nct_id":"NCT00451542","title":"Divalproex vs. Lamotrigine for Bipolar Disorder","phase":"","overall_status":"TERMINATED","enrollment_count":1000,"lead_sponsor_name":"Tuscaloosa Research & Education Advancement Corporation","has_results":false},{"nct_id":"NCT06657430","title":"A Study on the Preference of Risperidone Dosage Forms","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT06665984","title":"Greater Houston Area Pediatric Bipolar Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":false},{"nct_id":"NCT04229875","title":"The CAG Bipolar the CAG Bipolar RCT","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","has_results":false},{"nct_id":"NCT03573297","title":"A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":901,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06408012","title":"An Innovative Master Platform for Clinical Trials in Mood Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"St. Joseph's Healthcare Hamilton","has_results":false},{"nct_id":"NCT04209296","title":"Chart Review of Patients Undergoing Ketamine Infusions","phase":"","overall_status":"COMPLETED","enrollment_count":891,"lead_sponsor_name":"Brain and Cognition Discovery Foundation","has_results":false},{"nct_id":"NCT05801562","title":"Development of a Software Tool, Using Artificial Intelligence, That Integrates Clinical, Biological, Genetic and Imaging Data to Predict Diagnosis and Outcome of Depressed Patients in Order to Enhance Prognosis and Limiting Healthcare Costs.","phase":"","overall_status":"UNKNOWN","enrollment_count":730,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06053346","title":"Partners in Wellness: Evaluation of a Pay for Performance Program for High-Utilizers of Mental Health Services","phase":"NA","overall_status":"COMPLETED","enrollment_count":652,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT07031817","title":"Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":623,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05127837","title":"CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies","phase":"NA","overall_status":"COMPLETED","enrollment_count":601,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT05529576","title":"Multi-factor Model Constraction for Early Warning and Diagnosis of MDD","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT06424613","title":"Effects of Lithium on Suicide Prevention in Adolescents and Young Adults With Bipolar Disorder in China","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT07033923","title":"Neuro-computational Study of Thymic Fluctuations in Mood Disorders","phase":"NA","overall_status":"RECRUITING","enrollment_count":588,"lead_sponsor_name":"Centre Hospitalier St Anne","has_results":false},{"nct_id":"NCT05064995","title":"BIPLONG - The Bipolar Disorder in the Longitudinal Course","phase":"","overall_status":"UNKNOWN","enrollment_count":560,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT07151846","title":"Digital Phenotypes for Predicting Depression","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":540,"lead_sponsor_name":"Korea University Anam Hospital","has_results":false},{"nct_id":"NCT04812379","title":"Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)","phase":"","overall_status":"COMPLETED","enrollment_count":535,"lead_sponsor_name":"Otsuka Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04580134","title":"CLOZAPINE Response in Biotype-1","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":524,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03201757","title":"Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":523,"lead_sponsor_name":"Alkermes, Inc.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}